Linux fréttir

Michael Saylor's software company Strategy, formerly known as MicroStrategy, built a financial model that some observers called an "infinite-money machine" by stockpiling hundreds of thousands of bitcoins and issuing stock and debt to buy more, but that machine appears to be breaking down. The company's stock peaked above $450 in mid-July and ended November at $177.18, a 60% decline. Bitcoin fell only 25% over the same period. The gap between Strategy's market cap and the value of its bitcoin holdings has nearly vanished. At one point last week, the company's market value dipped below the value of its bitcoins after accounting for debt. Strategy announced it had built a $1.4 billion dollar reserve by selling more stock to cover required dividend payments to preferred shareholders over the next twelve months. The company also disclosed it might sell some of its coins if its value continues to fall, a reversal from Saylor's February tweet declaring "Never sell your Bitcoin." Professional short seller Jim Chanos, who had questioned the strategy's sustainability, told Sherwood he made money by shorting the stock and buying bitcoins.

Read more of this story at Slashdot.

Satellite silence trips immobilizers, leaving owners stuck

Hundreds of Porsches in Russia were rendered immobile last week, raising speculation of a hack, but the German carmaker tells The Register that its vehicles are secure.…

Trixie may have gone 64-bit for installs, but WMLive still ships an i686-bootable build

Window Maker Live 13.2 is stubbornly keeping 32-bit PCs alive on Debian 13 "Trixie," shipping a new release that boots on i686 hardware.…

Bad for consumers, bad for the environment, 230+ groups say

More than 230 organizations across America have signed a letter calling for a moratorium on the construction of datacenters, claiming the current building boom represents a huge environmental and social threat.…

Microsoft's Xbox consoles were conspicuously absent from Black Friday's winners, failing to crack the top three in U.S. sales during one of the retail calendar's most important weeks. According to Circana analyst Mat Piscatella, the PlayStation 5 captured 47% of Black Friday week console sales ending November 29, followed by the Nintendo Switch 2 at 24% and -- somewhat remarkably -- the NEX Playground, a Kinect-like Android device aimed at children, at 14%. Microsoft ran no promotions on its consoles during the period. The Xbox Series X currently retails for $650 following this year's price increase, up from its $500 launch price in 2020. Sony, by contrast, discounted the PS5 by roughly 40% at some retailers. Piscatella noted on Bluesky that products without price promotions typically see no seasonal lift. Costco has removed Xbox consoles from its U.S. and UK websites.

Read more of this story at Slashdot.

In February, a six-month-old baby named KJ Muldoon became the first person ever to receive a CRISPR gene-editing treatment customized specifically for his unique genetic mutation, a milestone that researchers say marks a turning point in how medicine might approach the thousands of rare diseases that collectively affect 30 million Americans. Muldoon was born with a type of urea-cycle disorder that gives patients roughly a 50% chance of surviving infancy and typically requires a liver transplant; he is now a healthy 1-year-old who recently took his first steps. The treatment's significance extends beyond one child. Scientists at UC Berkeley's Innovative Genomics Institute and the Children's Hospital of Philadelphia are now planning clinical trials that would use Muldoon's therapy as a template, tweaking the molecular "address" in the CRISPR system to target different mutations in other children with urea-cycle disorders. Last month, FDA officials Marty Makary and Vinay Prasad announced a new drug pathway designed to accelerate approvals for such personalized treatments -- a framework inspired in large part by Muldoon's case. Current gene-editing delivery mechanisms limit treatments to disorders in the blood and liver. Many families will still go without bespoke therapies.

Read more of this story at Slashdot.